Among these proteins, the p-RPS6 level and the degree of its response to the treated drugs could predict the susceptibility of breast cancer cells to not only trastuzumab but also other drugs, including rapamycin, AZD2014, BEZ235, erlotinib, lapatinib, MK226, and OSI-906. The gene discussed is RPS6; the disease is breast carcinoma.